Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Iovance Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
Pfizer
Novartis
Pfizer
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
Pheon Therapeutics
Pfizer
NeoImmuneTech
ToLymph Inc.
Hoffmann-La Roche
Nuvectis Pharma, Inc.
AstraZeneca
Istituto Oncologico Veneto IRCCS
AstraZeneca
Avenzo Therapeutics, Inc.
Boehringer Ingelheim
Shanghai Pulmonary Hospital, Shanghai, China
AstraZeneca
Pheon Therapeutics
Auricula Biosciences Inc.
DualityBio Inc.
Revolution Medicines, Inc.
Inhibrx Biosciences, Inc
Tanabe Pharma America, Inc.
Adaptimmune
CRISPR Therapeutics
AstraZeneca
AstraZeneca
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Genelux Corporation
Institut Bergonié
Sanofi
Trans Tasman Radiation Oncology Group
University Health Network, Toronto
Marengo Therapeutics, Inc.
AstraZeneca
Hoffmann-La Roche
Numab Therapeutics AG
Stanford University
Kiromic BioPharma Inc.
Intensity Therapeutics, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Iovance Biotherapeutics, Inc.
Simcha IL-18, Inc.
Cancer Research UK